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Introduction:We planned to reduce early transplant related
mortality associated with conventional allogeneic hemato-
poietic stem cell transplantation (HSCT) and reduce acute or
chronic GvHD related to non-myeloablative allo HSCT while
maintaining the graft-versus-myeloma effect for patients
with high-risk multiple myeloma.
Methods: 34 pts using allo T-cell depleted (TCD) HSCT from
HLA compatible (matched related¼ 12, matched unrelated¼
13, and mismatched unrelated ¼ 9) donors. All 34 pts had
relapsed myeloma within 15 mos following auto HSCT, and
26/34 pts also had high-risk cytogenetics at diagnosis
[t(4;14), t(14;16), del17p by FISH and/or del13q by kar-
yotyping] are reported. All pts had to achieve at least a partial
response from salvage chemotherapy (n¼26) salvage auto
HSCT (n ¼8). Pts underwent allo TCD HSCT with busulfan
(0.8mg/kg x 10 doses), melphalan (70mg/m2 x 2 days), ﬂu-
darabine (25mg/m2 x 5 days) and rabbit ATG (2.5mg/kg x 2
days). T-cell depletion was performed by positive CD34 se-
lection (Isolex) followed by rosetting with sheep erythro-
cytes for the initial 13pts (2008-09) and by CD34+
enrichment by the Miltenyi Device in 21pts thereafter,
achieving < 104CD3+/kg for all grafts. None of these pts
received immuno suppressive therapy post TCD HSCT. Pts
were also eligible to receive low doses of donor lymphocyte
infusions (DLI) (5x10e5 e 1x10e6 CD3+/kg) no earlier than
5mos post allo HSCT.
Results: 34 pts with a median follow up of 33.6mos (range:
9.6 e 67.1 mos) of survivors are reported, median age 56
years (range 32 e 69). TRM and acute GvHD (grade II-IV) at
12mos is 9% (95% CI: 2% e 23%) and 6% (95% CI: 1% e 17%).
Chronic GvHD was not observed in any pt. OS and PFS with
their 95% CI are shown in Table 1. Factors associated with
worse outcome were disease status and number of previousTable 1
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0.0treatments prior to TCD HSCT. 15/34 pts are alive, 10/15 pts
are in complete remission (CR), 4 pts are have been in
continued CR for 46, 55, 64 and 67mos post allo TCD HSCT. 5/
15 pts alive have progressed and 4/5 pts are currently
responding to salvage chemotherapy and/or DLI. 14/19pts pts
died of disease progression, 3/19 died of infectious compli-
cations and 2 pts died of complications associated with acute
GvHD.
Conclusion: Long-lasting disease control can be achieved
with TCD HSCT in pts with multiply relapsed MM including
those with high-risk cytogenetics. TRM and GvHD are low in
these heavily pretreated pts. Outcome of TCD HSCT is inﬂu-
enced by numbers of regimens administered and disease
status prior to allo BMT.25
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We retrospectively analysed 386 cases of relapsed acute
myeloid leukaemia (AML) from 1336 allogeneic haemato-
poietic stem cell transplants (alloHSCT) performed between
2000-2011, with two aims: 1. To ﬁnd and validate factors
available at time of relapse that would predict for overall sur-
vival from relapse (OS). 2. To determine the effect of ﬁrst
salvage therapy and subsequent GVHD on OS. Aim 1: 349
analysable patientswere randomly split into training (n¼ 233)
and validation (n ¼ 116) cohorts. The cohorts were compara-
ble; the only signiﬁcant difference was more HLA-matched
